Your browser doesn't support javascript.
loading
The viral protein corona directs viral pathogenesis and amyloid aggregation.
Ezzat, Kariem; Pernemalm, Maria; Pålsson, Sandra; Roberts, Thomas C; Järver, Peter; Dondalska, Aleksandra; Bestas, Burcu; Sobkowiak, Michal J; Levänen, Bettina; Sköld, Magnus; Thompson, Elizabeth A; Saher, Osama; Kari, Otto K; Lajunen, Tatu; Sverremark Ekström, Eva; Nilsson, Caroline; Ishchenko, Yevheniia; Malm, Tarja; Wood, Matthew J A; Power, Ultan F; Masich, Sergej; Lindén, Anders; Sandberg, Johan K; Lehtiö, Janne; Spetz, Anna-Lena; El Andaloussi, Samir.
Afiliação
  • Ezzat K; Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, 10691, Sweden. kariem.ezzat@su.se.
  • Pernemalm M; Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Stockholm, 14152, Sweden. kariem.ezzat@su.se.
  • Pålsson S; Clinical Proteomics Mass Spectrometry, Department of Oncology-Pathology, Science for Life Laboratory and Karolinska Institutet, Stockholm, 17176, Sweden.
  • Roberts TC; Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, 10691, Sweden.
  • Järver P; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX13PT, UK.
  • Dondalska A; Sanford Burnham Prebys Medical Discovery Institute, Development, Aging and Regeneration Program, La Jolla, CA, 92037, USA.
  • Bestas B; Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, 10691, Sweden.
  • Sobkowiak MJ; Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, 10691, Sweden.
  • Levänen B; Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Stockholm, 14152, Sweden.
  • Sköld M; Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Gothenburg, Sweden.
  • Thompson EA; Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, 14186, Sweden.
  • Saher O; Unit for Lung and Airway disease, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, 17165, Sweden.
  • Kari OK; Respiratory Medicine Unit, Department of Medicine, Karolinska Institutet, Stockholm, 17176, Sweden.
  • Lajunen T; Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, 17176, Sweden.
  • Sverremark Ekström E; Immunology and Allergy Unit, and Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, 17176, Sweden.
  • Nilsson C; Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Stockholm, 14152, Sweden.
  • Ishchenko Y; Faculty of Pharmacy, Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo, 11562, Egypt.
  • Malm T; Drug Research Program, Faculty of Pharmacy, Division of Pharmaceutical Biosciences, University of Helsinki, Helsinki, 00014, Finland.
  • Wood MJA; Drug Research Program, Faculty of Pharmacy, Division of Pharmaceutical Biosciences, University of Helsinki, Helsinki, 00014, Finland.
  • Power UF; Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, 10691, Sweden.
  • Masich S; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet and Sachs' Children and Youth Hospital, Stockholm, 11883, Sweden.
  • Lindén A; A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 70211, Finland.
  • Sandberg JK; A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 70211, Finland.
  • Lehtiö J; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX13PT, UK.
  • Spetz AL; Centre of Experimental Medicine, Queens' University Belfast, Belfast, BT97BL, UK.
  • El Andaloussi S; Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 17177, Sweden.
Nat Commun ; 10(1): 2331, 2019 05 27.
Article em En | MEDLINE | ID: mdl-31133680
ABSTRACT
Artificial nanoparticles accumulate a protein corona layer in biological fluids, which significantly influences their bioactivity. As nanosized obligate intracellular parasites, viruses share many biophysical properties with artificial nanoparticles in extracellular environments and here we show that respiratory syncytial virus (RSV) and herpes simplex virus type 1 (HSV-1) accumulate a rich and distinctive protein corona in different biological fluids. Moreover, we show that corona pre-coating differentially affects viral infectivity and immune cell activation. In addition, we demonstrate that viruses bind amyloidogenic peptides in their corona and catalyze amyloid formation via surface-assisted heterogeneous nucleation. Importantly, we show that HSV-1 catalyzes the aggregation of the amyloid ß-peptide (Aß42), a major constituent of amyloid plaques in Alzheimer's disease, in vitro and in animal models. Our results highlight the viral protein corona as an acquired structural layer that is critical for viral-host interactions and illustrate a mechanistic convergence between viral and amyloid pathologies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Peptídeos beta-Amiloides / Vírus Sincicial Respiratório Humano / Herpesvirus Humano 1 / Interações Hospedeiro-Patógeno / Coroa de Proteína Tipo de estudo: Etiology_studies Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Peptídeos beta-Amiloides / Vírus Sincicial Respiratório Humano / Herpesvirus Humano 1 / Interações Hospedeiro-Patógeno / Coroa de Proteína Tipo de estudo: Etiology_studies Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article